These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2876514)

  • 21. A comparison of patients who refuse and consent to neuroleptic treatment.
    Marder SR; Mebane A; Chien CP; Winslade WJ; Swann E; Van Putten T
    Am J Psychiatry; 1983 Apr; 140(4):470-2. PubMed ID: 6132559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual and negative symptoms in treatment with neuroleptics.
    Kane JM
    Psychopharmacol Ser; 1993; 10():131-7. PubMed ID: 8103222
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment response scale: a retrospective method of assessing response to neuroleptics.
    Csernansky JG; Yesavage JA; Maloney W; Kaplan J
    Am J Psychiatry; 1983 Sep; 140(9):1210-3. PubMed ID: 6137150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 28. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics.
    Beckmann H; Fritze J; Franzek E
    Neuropsychobiology; 1992; 26(1-2):50-8. PubMed ID: 1361971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schizoaffective disorder: a form of schizophrenia or affective disorder?
    Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
    J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in semantic information processing in schizophrenics.
    Volz HP; Mackert A; Frick K; Bücker U
    Pharmacopsychiatry; 1994 Mar; 27(2):59-62. PubMed ID: 7913235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of the Kamin blocking effect in acute but not chronic schizophrenics.
    Jones SH; Gray JA; Hemsley DR
    Biol Psychiatry; 1992 Nov; 32(9):739-55. PubMed ID: 1360261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of thought disorder in paranoid and non-paranoid schizophrenia.
    Mazumdar PK; Chaturvedi SK; Gopinath PS
    Psychopathology; 1991; 24(3):166-9. PubMed ID: 1754647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
    Woggon B; Bickel P; Schnyder B
    Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The early course of schizophrenic thought disorder.
    Harrow M; Marengo J; McDonald C
    Schizophr Bull; 1986; 12(2):208-24. PubMed ID: 3715415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A preliminary report of a strong genetic component for thought disorder in normals. A twin study.
    Gambini O; Campana A; Macciardi F; Scarone S
    Neuropsychobiology; 1997; 36(1):13-8. PubMed ID: 9211438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quality of life of schizophrenic patients and clozapine].
    Raoul Y; Manesse P; Delage M
    Encephale; 1997 Sep; 23 Spec No 4():12-6. PubMed ID: 9417398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.